NasdaqGM:KODBiotechs
Kodiak Sciences (KOD) Valuation Check After Positive APEX Phase 1b Macular Edema Results
Kodiak Sciences (KOD) is back in focus after announcing it will share first-time, end-of-study Phase 1b APEX data in macular edema at the Angiogenesis, Exudation, and Degeneration 2026 conference.
See our latest analysis for Kodiak Sciences.
The APEX data update comes after a sharp 1 day share price return of 9.66%, though the 30 day share price return of a 14.89% decline contrasts with a 30.69% gain over 90 days and a very large 1 year total shareholder return.
If Kodiak Sciences has you...